Tazeen Ahmad
BofA Securities, Research Division

[Audio Gap] chatting with Kymera Therapeutics. Up here on stage, we've got a couple of members from the management team. We've got Bruce Jacobs, who's, of course, is Chief Financial Officer; as well as Jared Gollob, who is the Chief Medical Officer. Gentlemen, thanks for making the trip over from Boston.

Bruce Jacobs
Chief Financial Officer

Thank you.

Jared Gollob
Chief Medical Officer

Thanks for having us.

Tazeen Ahmad
BofA Securities, Research Division

So maybe we can just start off with a quick overview of the company. Maybe talk to us about atopic dermatitis is a very, very popular space to be looking at these days. That's just one of the many things that you've got going. Can you just talk in general about the platform and how you differentiate from others who might be pursuing similar indications, and then we can go into more specifics from there.

Bruce Jacobs
Chief Financial Officer

Sure. Thanks, Tazeen. Maybe I'll start, and Jared can chime in. So it's a good time for that question. Kymera actually last week celebrated our 10-year anniversary of the company's founding, May 4, 2016. So it's been a great opportunity for us to reflect on all that we've accomplished over that time, but also what we still have in front of us. But the company obviously was founded at the time on the promise of targeted protein degradation. And since that time, I think we've been incredibly productive as a discovery engine.

We've taken now 6 programs into the